Sofie Verbeke
YOU?
Author Swipe
View article: Genomic Predictors of Response to Metastasis-directed Therapy With or Without Androgen Deprivation Therapy
Genomic Predictors of Response to Metastasis-directed Therapy With or Without Androgen Deprivation Therapy Open
Metastasis-directed therapy (MDT) is an emerging treatment option for metachronous oligometastatic castration-sensitive prostate cancer (omCSPC) and can delay time to progression and the need to initiate androgen deprivation therapy (ADT).…
View article: Retrospective analysis of multiparametric MRI in Predicting Complete Pathologic Response of Neo-adjuvant Chemotherapy in Bladder Cancer
Retrospective analysis of multiparametric MRI in Predicting Complete Pathologic Response of Neo-adjuvant Chemotherapy in Bladder Cancer Open
Background Muscle invasive bladder cancer (MIBC) treatment combines systemic therapy and radical cystectomy (RC) or local (chemo-)radiotherapy. Response to systemic therapy is an important outcome predictor but is difficult to assess pre-o…
View article: Supplementary Figures, Tables, Notes from Whole Slide Imaging-Based Prediction of <i>TP53</i> Mutations Identifies an Aggressive Disease Phenotype in Prostate Cancer
Supplementary Figures, Tables, Notes from Whole Slide Imaging-Based Prediction of <i>TP53</i> Mutations Identifies an Aggressive Disease Phenotype in Prostate Cancer Open
Supplementary Figures, Tables and Notes
View article: Data from Whole Slide Imaging-Based Prediction of <i>TP53</i> Mutations Identifies an Aggressive Disease Phenotype in Prostate Cancer
Data from Whole Slide Imaging-Based Prediction of <i>TP53</i> Mutations Identifies an Aggressive Disease Phenotype in Prostate Cancer Open
In prostate cancer, there is an urgent need for objective prognostic biomarkers that identify the metastatic potential of a tumor at an early stage. While recent analyses indicated TP53 mutations as candidate biomarkers, molecular profilin…
View article: Suppl Data 2 from Whole Slide Imaging-Based Prediction of <i>TP53</i> Mutations Identifies an Aggressive Disease Phenotype in Prostate Cancer
Suppl Data 2 from Whole Slide Imaging-Based Prediction of <i>TP53</i> Mutations Identifies an Aggressive Disease Phenotype in Prostate Cancer Open
Contains 1. significantly differentially expressed genes between samples with high and low gleason grade ("Gleason_high_low"), 2. the pathway overrepresentations for these genes ("MSigDB_Gleason_HL", "Reactome_Gleason_HL"), 3. the overlapp…
View article: Suppl. Data 1 from Whole Slide Imaging-Based Prediction of <i>TP53</i> Mutations Identifies an Aggressive Disease Phenotype in Prostate Cancer
Suppl. Data 1 from Whole Slide Imaging-Based Prediction of <i>TP53</i> Mutations Identifies an Aggressive Disease Phenotype in Prostate Cancer Open
Contains 1. significantly differentially expressed genes between eTN and eFP ("FP_TN"), 2. significantly differentially expressed genes between eTN and eTP ("TP_TN"), 3. the pathway overrepresentations for 2-3. ("Reactome_table_FP_TN", "Re…
View article: Data from Whole Slide Imaging-Based Prediction of <i>TP53</i> Mutations Identifies an Aggressive Disease Phenotype in Prostate Cancer
Data from Whole Slide Imaging-Based Prediction of <i>TP53</i> Mutations Identifies an Aggressive Disease Phenotype in Prostate Cancer Open
In prostate cancer, there is an urgent need for objective prognostic biomarkers that identify the metastatic potential of a tumor at an early stage. While recent analyses indicated TP53 mutations as candidate biomarkers, molecular profilin…
View article: Supplementary Figures, Tables, Notes from Whole Slide Imaging-Based Prediction of <i>TP53</i> Mutations Identifies an Aggressive Disease Phenotype in Prostate Cancer
Supplementary Figures, Tables, Notes from Whole Slide Imaging-Based Prediction of <i>TP53</i> Mutations Identifies an Aggressive Disease Phenotype in Prostate Cancer Open
Supplementary Figures, Tables and Notes
View article: Suppl. Data 1 from Whole Slide Imaging-Based Prediction of <i>TP53</i> Mutations Identifies an Aggressive Disease Phenotype in Prostate Cancer
Suppl. Data 1 from Whole Slide Imaging-Based Prediction of <i>TP53</i> Mutations Identifies an Aggressive Disease Phenotype in Prostate Cancer Open
Contains 1. significantly differentially expressed genes between eTN and eFP ("FP_TN"), 2. significantly differentially expressed genes between eTN and eTP ("TP_TN"), 3. the pathway overrepresentations for 2-3. ("Reactome_table_FP_TN", "Re…
View article: Suppl Data 2 from Whole Slide Imaging-Based Prediction of <i>TP53</i> Mutations Identifies an Aggressive Disease Phenotype in Prostate Cancer
Suppl Data 2 from Whole Slide Imaging-Based Prediction of <i>TP53</i> Mutations Identifies an Aggressive Disease Phenotype in Prostate Cancer Open
Contains 1. significantly differentially expressed genes between samples with high and low gleason grade ("Gleason_high_low"), 2. the pathway overrepresentations for these genes ("MSigDB_Gleason_HL", "Reactome_Gleason_HL"), 3. the overlapp…
View article: Whole Slide Imaging-Based Prediction of <i>TP53</i> Mutations Identifies an Aggressive Disease Phenotype in Prostate Cancer
Whole Slide Imaging-Based Prediction of <i>TP53</i> Mutations Identifies an Aggressive Disease Phenotype in Prostate Cancer Open
In prostate cancer, there is an urgent need for objective prognostic biomarkers that identify the metastatic potential of a tumor at an early stage. While recent analyses indicated TP53 mutations as candidate biomarkers, molecular profilin…
View article: Radiotherapy Use in Muscle-Invasive Bladder Cancer: Review of the Guidelines and Impact of Increased Awareness in Patient Referral at a Tertiary Center in Belgium
Radiotherapy Use in Muscle-Invasive Bladder Cancer: Review of the Guidelines and Impact of Increased Awareness in Patient Referral at a Tertiary Center in Belgium Open
We provide a critical overview of the RT indications in MIBC as recommended by the international guidelines. Increased awareness about RT as a treatment option in MIBC seems to have an impact on the treatment choice in clinical practice, a…
View article: Is It Safe to Switch from a Standard Anterior to Retzius-Sparing Approach in Robot-Assisted Radical Prostatectomy?
Is It Safe to Switch from a Standard Anterior to Retzius-Sparing Approach in Robot-Assisted Radical Prostatectomy? Open
Background: Retzius-sparing robot-assisted radical prostatectomy (RS-RARP) has been shown to lead to better outcomes regarding early continence compared to standard anterior RARP (SA-RARP). The goal of this study was to assess the feasibil…
View article: Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials
Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials Open
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co‐primary or secondary analyses are not yet available. …
View article: Genomic Features of Lung-Recurrent Hormone-Sensitive Prostate Cancer
Genomic Features of Lung-Recurrent Hormone-Sensitive Prostate Cancer Open
PURPOSE Pulmonary involvement is rare in metastatic hormone-sensitive prostate cancer (mHSPC) that recurs after treatment for localized disease. Guidelines recommend intensive systemic therapy, similar to patients with liver metastases, bu…
View article: Adjuvant Radiotherapy After Radical Cystectomy for Patients with High-risk Muscle-invasive Bladder Cancer: Results of a Multicentric Phase II Trial
Adjuvant Radiotherapy After Radical Cystectomy for Patients with High-risk Muscle-invasive Bladder Cancer: Results of a Multicentric Phase II Trial Open
In this report, we looked at the incidence of toxicity and local control after adjuvant external beam radiotherapy (EBRT) following radical cystectomy (RC) in high-risk muscle-invasive bladder cancer patients. We found that adjuvant EBRT w…
View article: Evaluating the impact of 18F-FDG-PET-CT on risk stratification and treatment adaptation for patients with muscle-invasive bladder cancer (EFFORT-MIBC): a phase II prospective trial
Evaluating the impact of 18F-FDG-PET-CT on risk stratification and treatment adaptation for patients with muscle-invasive bladder cancer (EFFORT-MIBC): a phase II prospective trial Open
Background The outcome of patients with muscle-invasive bladder cancer (MIBC) remains poor, despite aggressive treatments. Inadequate primary staging, classically performed by computed tomography (CT)-imaging, could lead to inappropriate t…
View article: MP24-10 NEWLY-DIAGNOSED LOW-VOLUME METASTATIC PROSTATE CANCER; IS THERE A PLACE FOR CYTOREDUCTIVE RADICAL PROSTATECTOMY?
MP24-10 NEWLY-DIAGNOSED LOW-VOLUME METASTATIC PROSTATE CANCER; IS THERE A PLACE FOR CYTOREDUCTIVE RADICAL PROSTATECTOMY? Open
You have accessJournal of UrologyProstate Cancer: Advanced (including Drug Therapy) II (MP24)1 Sep 2021MP24-10 NEWLY-DIAGNOSED LOW-VOLUME METASTATIC PROSTATE CANCER; IS THERE A PLACE FOR CYTOREDUCTIVE RADICAL PROSTATECTOMY? Elise De Bleser…
View article: Shallow-depth sequencing of cell-free DNA for Hodgkin and diffuse large B-cell lymphoma (differential) diagnosis: a standardized approach with underappreciated potential
Shallow-depth sequencing of cell-free DNA for Hodgkin and diffuse large B-cell lymphoma (differential) diagnosis: a standardized approach with underappreciated potential Open
Shallow-depth sequencing of cell-free DNA, an inexpensive and standardized approach to obtain molecular information on tumors non-invasively, has been insufficiently explored for the diagnosis of lymphoma and disease follow-up. This study …